Skip to main content
OpenTrials
Completed

NCT Number: NCT02187536

Pharmacokinetics of Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan in Healthy Subjects

To assess the pharmacokinetics of simvastatin and simvastatin acid with/without concomitant administration of telmisartan

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects as determined by results of screening
  • Signed written informed consent in accordance with good clinical practice (GCP) and local legislation
  • Age ≥ 18 and ≤ 55 years
  • Broca ≥ -20 % and ≤ +20 %

Exclusion criteria

  • Any findings of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastro-intestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • Supine blood pressure at screening of systolic ≤ 110 mmHg and diastolic ≤ 60 mmHg
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infection
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half life (> 24 hours) ≤ 1 month prior to administration or during the trial
  • Use of any drugs which might influence the results of the trial (≤ 10 days prior to administration or during the trial)
  • Participation in another trial with an investigational drug (30 days prior to administration or during the trial)
  • Smoker
  • Alcohol abuse (> 60 g/day)
  • Drug abuse
  • Blood donation (≤ 1 month prior to administration or during the trial)
  • Excessive physical activities (≤ 5 days prior to administration or during the trial)
  • Any laboratory value outside the reference range of clinical relevance
  • Hypersensitivity to telmisartan and/or simvastatin and/or related classes of drugs

For female subjects:

  • Pregnancy
  • Positive pregnancy test
  • No adequate contraception (e.g. sterilization, intrauterine device (IUD), oral contraceptives)
  • Inability to maintain this adequate contraception during the whole study period
  • Lactation period

Treatment and study plan

Telmisartan

Drug

simvastatin

Drug

Telmisartan placebo

Drug

Primary outcomes

  1. Area under the concentration-time curve of simvastatin and simvastatin acid in plasma at different time points (AUC)

    Time frame: Pre-dose, up to day 32 after start of treatment

  2. Maximum concentration of simvastatin and simvastatin acid in plasma (Cmax)

    Time frame: Pre-dose, up to day 32 after start of treatment

Secondary outcomes

  1. Time to Cmax after a single extravascular dose (tmax)

    Time frame: Pre-dose, up to day 32 after start of treatment

  2. Elimination half-life in plasma (t1/2)

    Time frame: Pre-dose, up to day 32 after start of treatment

  3. Total clearance from plasma (CLtot/f)

    Time frame: Pre-dose, up to day 32 after start of treatment

  4. Mean time of residence in the body (MRTtot)

    Time frame: Pre-dose, up to day 32 after start of treatment

  5. Apparent volume of distribution during the terminal phase (Vz/f)

    Time frame: Pre-dose, up to day 32 after start of treatment

  6. Area under the plasma concentration-time curve of telmisartan at steady state (AUCss)

    Time frame: Pre-dose, up to day 32 after start of treatment

  7. Maximum concentration of telmisartan in plasma at steady state (Cmax,ss)

    Time frame: Pre-dose, up to day 32 after start of treatment

  8. Number of patients with clinically relevant findings in laboratory values

    Time frame: Pre-dose, up to day 32 after start of treatment

  9. Number of patients with clinically relevant findings in vital signs (blood pressure, pulse rate)

    Time frame: Pre-dose, up to day 32 after start of treatment

  10. Number of patients with adverse events

    Time frame: Up to day 32 after start of treatment

  11. Number of patients with clinically relevant findings in ECG

    Time frame: Pre-dose, up to day 32 after start of treatment

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Pharmacokinetics of Single Oral Doses of 40 mg Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan 80 mg Daily, Given Orally Over 6 Days. A Randomised, Placebo Controlled, Double Blind (for Telmisartan), Two Way Cross Over Trial in Healthy Subjects

Important dates

Study start
2000
Primary completion
2000
First posted
Jul 11, 2014
Registry last updated
Jul 11, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.